SCHEDULE: Venrock Group Amends 3.2% Stake in Cidara Therapeutics
Beneficial Ownership Report (Amendment)
A group of Venrock entities and individuals filed an amended Schedule 13G, disclosing a continued beneficial ownership of 3.2% in Cidara Therapeutics, Inc.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
- The Reporting Persons collectively beneficially own 639,088 shares of Cidara Therapeutics, Inc. Common Stock.
- This aggregate amount represents 3.2% of the Issuer's outstanding Common Stock.
- The percentage is based on 20,163,696 shares of Common Stock outstanding as of June 26, 2025, as reported in Cidara Therapeutics' prospectus supplement dated June 24, 2025.
- The ownership is distributed among the entities as follows: 134,554 shares by VHCP III, 13,456 shares by VHCP Co-Investment III, and 491,078 shares by VHCP EG.
- All Reporting Persons share voting and dispositive power over the 639,088 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, indicating no significant positive or negative sentiment regarding the company's operations or prospects.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.
Industry Context
This filing reflects a routine disclosure of institutional ownership in a biotechnology company, common for investment firms like Venrock Healthcare Capital Partners. It indicates continued investment interest in Cidara Therapeutics by this specific group.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming a continued stake by the Venrock group.
Key Dates
| Date | Description |
|---|---|
| 2025-06-24 | Date of Issuer's prospectus supplement reporting shares outstanding. |
| 2025-06-25 | Date Issuer's prospectus supplement was filed with the SEC. |
| 2025-06-26 | Date for which 20,163,696 shares of Common Stock were reported outstanding. |
| 2025-06-30 | Date of event which requires filing of this statement (snapshot date for beneficial ownership). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Cidara Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Healthcare Investment, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.